Could Systemic Inflammation-Based Prognostic ScoresPredict the Clinical Outcome in Patients with Breast CancerTreated with Everolimus Plus Exemestane?

Basit Öğe Kaydı
dc.contributor.authorÇelik, Emir
dc.contributor.authorSamancı, Nilay Sengul
dc.contributor.authorKaradağ, Mehmet
dc.contributor.authorDemirci, Nebi Serkan
dc.contributor.authorDemirelli, Fuat Hulusi
dc.date.accessioned2024-09-19T16:21:01Z
dc.date.available2024-09-19T16:21:01Z
dc.date.issued2021
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjectives: No study to clarify which inflammation score could best reflect survival in a cohort of metastatic breastcancer (mBC) patients who received everolimus plus exemestane. Methods: The impact of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI) on PFS and OS was evaluated. Results: A total of 80 mBC patients were included. Median PFS was 8.9 months and median overall survival (OS) was31.8 months. We found that there was no significant difference between NLR, PLR, SII, and PNI groups for median PFSand OS. Conclusion: Inflammation-based prognostic scores were not correlated with prognosis in patients with mBC who hadbeen treated with everolimus plus exemestane.en_US
dc.identifier.doi10.14744/ejmi.2021.21203
dc.identifier.endpage231en_US
dc.identifier.issn2602-3164
dc.identifier.issue2en_US
dc.identifier.startpage225en_US
dc.identifier.trdizinid485336en_US
dc.identifier.urihttps://doi.org/10.14744/ejmi.2021.21203
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/485336
dc.identifier.urihttps://hdl.handle.net/20.500.12483/15525
dc.identifier.volume5en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofEurasian Journal of Medical Investigationen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleCould Systemic Inflammation-Based Prognostic ScoresPredict the Clinical Outcome in Patients with Breast CancerTreated with Everolimus Plus Exemestane?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
15525.pdf
Boyut:
173.93 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu